Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.

PubWeight™: 2.32‹?› | Rank: Top 2%

🔗 View Article (PMID 18166787)

Published in Haematologica on January 01, 2008

Authors

Pau Montesinos1, Ignacio Lorenzo, Guillermo Martín, Jaime Sanz, Maria Luz Pérez-Sirvent, David Martínez, Guillermo Ortí, Lorenzo Algarra, Jesus Martínez, Federico Moscardó, Javier de la Rubia, Isidro Jarque, Guillermo Sanz, Miguel A Sanz

Author Affiliations

1: Hematology Service, Hospital Universitario La Fe, Avenida Campanar 21, 46019, Valencia, Spain.

Associated clinical trials:

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | NCT04112589

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | NCT04687761

Articles citing this

The tumor lysis syndrome. N Engl J Med (2011) 4.29

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol (2010) 1.74

Tumor lysis syndrome: current perspective. Haematologica (2008) 1.42

Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis (2014) 1.11

Tumor lysis syndrome: A clinical review. World J Crit Care Med (2015) 0.85

Kidney diseases associated with haematological cancers. Nat Rev Nephrol (2015) 0.83

Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens. J Investig Med High Impact Case Rep (2015) 0.83

Acute renal failure and type B lactic acidosis as first manifestation of extranodal T-cell lymphoblastic lymphoma. BMJ Case Rep (2014) 0.82

Spontaneous tumour lysis syndrome associated with contrast dye iohexol use in mantle cell lymphoma. BMJ Case Rep (2014) 0.80

Interferences and Limitations in Blood Glucose Self-Testing: An Overview of the Current Knowledge. J Diabetes Sci Technol (2016) 0.77

How I treat acute myeloid leukemia presenting with preexisting comorbidities. Blood (2016) 0.77

Uric acid and the prediction models of tumor lysis syndrome in AML. PLoS One (2015) 0.76

A focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologist. Semin Intervent Radiol (2015) 0.75

SIL-TAL1 rearrangement is related with poor outcome: a study from a Chinese institution. PLoS One (2013) 0.75

Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. Onco Targets Ther (2017) 0.75

Articles by these authors

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41

Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12

Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med (2004) 7.73

International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood (2008) 7.06

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med (2013) 6.21

Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet (2008) 3.74

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood (2011) 3.28

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99

Changes to the elevational limits and extent of species ranges associated with climate change. Ecol Lett (2005) 2.87

Risk factors for low birth weight: a review. Eur J Obstet Gynecol Reprod Biol (2004) 2.86

Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol (2004) 2.81

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood (2008) 2.74

Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol (2008) 2.74

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica (2008) 2.69

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood (2011) 2.58

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood (2006) 2.51

The tree of life and a new classification of bony fishes. PLoS Curr (2013) 2.50

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood (2012) 2.42

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood (2008) 2.34

Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood (2003) 2.27

Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood (2008) 2.27

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol (2008) 2.09

Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica (2002) 2.08

Incidence of Wra antigen and anti-Wra in a Spanish population. Transfusion (2005) 2.05

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood (2008) 2.04

[Guidelines for diagnosis, treatment and monitoring of primary immune thrombocytopenia]. Med Clin (Barc) (2012) 2.02

Phylogenetic relationships within the speciose family Characidae (Teleostei: Ostariophysi: Characiformes) based on multilocus analysis and extensive ingroup sampling. BMC Evol Biol (2011) 1.98

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood (2011) 1.94

Birth weight and prenatal exposure to polychlorinated biphenyls (PCBs) and dichlorodiphenyldichloroethylene (DDE): a meta-analysis within 12 European Birth Cohorts. Environ Health Perspect (2011) 1.84

Optimal data partitioning and a test case for ray-finned fishes (Actinopterygii) based on ten nuclear loci. Syst Biol (2008) 1.76

New findings do not support the neomaterialist theory of the relation between income inequality and infant mortality. Soc Sci Med (2011) 1.75

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood (2013) 1.74

A practical approach to phylogenomics: the phylogeny of ray-finned fish (Actinopterygii) as a case study. BMC Evol Biol (2007) 1.66

Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma (2006) 1.65

Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med (2006) 1.60

Spatial distribution and risk factors of Brucellosis in Iberian wild ungulates. BMC Infect Dis (2010) 1.59

Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol (2010) 1.57

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood (2008) 1.57

Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res (2006) 1.54

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood (2013) 1.54

Trends of socioeconomic inequalities and socioeconomic inequalities in self-perceived health in Spain. Gac Sanit (2006) 1.54

Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood (2007) 1.53

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant (2006) 1.53

Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol (2008) 1.53

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer (2011) 1.51

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood (2012) 1.50

Multi-locus phylogenetic analysis reveals the pattern and tempo of bony fish evolution. PLoS Curr (2013) 1.47

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica (2010) 1.44

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica (2009) 1.44

Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk Lymphoma (2013) 1.43

Acute myocardial infarction associated with Yasmin oral contraceptive. Clin Appl Thromb Hemost (2007) 1.40

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica (2009) 1.39

Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion (2002) 1.39

Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol (2007) 1.39

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica (2013) 1.32

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood (2013) 1.32

Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica (2003) 1.30

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol (2007) 1.29

Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica (2012) 1.28

Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica (2004) 1.28

Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant (2006) 1.28

Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica (2006) 1.27

Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res (2005) 1.27

Cord-blood transplantation in patients with leukemia--a real alternative for adults. N Engl J Med (2004) 1.24

Molecular phylogeny of Clupeiformes (Actinopterygii) inferred from nuclear and mitochondrial DNA sequences. Mol Phylogenet Evol (2006) 1.23

Effects of pre and postnatal exposure to low levels of polybromodiphenyl ethers on neurodevelopment and thyroid hormone levels at 4 years of age. Environ Int (2011) 1.23

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet (2002) 1.22

Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res (2005) 1.21

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol (2008) 1.20

Novel evolutionary relationship among four fish model systems. Trends Genet (2004) 1.20

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood (2010) 1.20

Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol (2005) 1.15

Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant (2010) 1.15

All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood (2004) 1.14

Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant (2009) 1.14

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol (2009) 1.14

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood (2012) 1.13

Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica (2008) 1.12

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood (2008) 1.11